A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)
Purpose
The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.
Condition
- Healthy
Eligibility
- Eligible Ages
- Between 18 Years and 55 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Be in good health - BMI between 18.5 and 32 kg/m2, inclusive
Exclusion Criteria
- History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological (history of a bleeding disorder, abnormal bleeding or a hereditary or acquired coagulation or platelet disorder), hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke, intercranial hemorrhage, and chronic seizures) abnormalities or diseases - History of cancer (malignancy)
Study Design
- Phase
- Phase 1
- Study Type
- Interventional
- Allocation
- Non-Randomized
- Intervention Model
- Sequential Assignment
- Primary Purpose
- Basic Science
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Period 1: Nemtabrutinib |
Participants will receive nemtabrutinib followed by a protocol specified wash-out period. |
|
|
Experimental Period 2: Diltiazem + Nemtabrutinib |
Participants will receive diltiazem plus nemtabrutinib. |
|
Recruiting Locations
Fortea CRU Madison (0001)
Madison 5261457, Wisconsin 5279468 53704
Madison 5261457, Wisconsin 5279468 53704
More Details
- Status
- Recruiting
- Sponsor
- Merck Sharp & Dohme LLC